On June 23, 2025 Oxcia reported that it has entered into an early research collaboration with LEO Pharma to explore OXC-101 in topical formulations for medical dermatology indications including psoriasis (Press release, Oxcia, JUN 23, 2025, View Source;utm_medium=rss&utm_campaign=oxcia-enters-a-research-collaboration-with-leo-pharma-to-explore-oxc-101-in-medical-dermatology [SID1234654058]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oxcia is developing an oral product, OXC-101, mainly for treatments of cancer. In one of Oxcia’s clinical trials, a cancer patient with plaque psoriasis experienced significant improvement in the disease during OXC-101 treatment, indicating that OXC-101 might also have potential in skin diseases, as previously seen in pre-clinical models. OXC-101 is a mitotic MTH1 inhibitor with biological rationale also to treat skin diseases.
This collaboration, aimed at exploring OXC-101 for medical dermatology, aligns with Oxcia’s vision of extending the application of its technology platform beyond cancer. LEO Pharma’s proven expertise and long-standing success in developing dermatology treatments that deliver significant therapeutic advancements make them the ideal partner to help explore the potential of Oxcia’s OXC-101.
"We are very happy about the collaboration with LEO Pharma, a leading global dermatology company. Cancer cells and activated T cells have many similarities, i.e. increased oxidative stress and heightened levels of the enzyme MTH1, meaning that OXC-101 has potential also in auto-immune diseases. Together with Professor Helleday and Professor Enerbäck’s research groups, Oxcia have shown that OXC-101 has good effects in disease models for psoriasis and it is exciting that this is now further investigated. The patient that responded well on OXC-101 treatment is encouraging and we are looking forward to seeing the results of the continued development. At Oxcia, we also see the psoriasis project as a confirmation of the potential and versatility of the O2-DDR platform" says Ulrika Warpman Berglund, CEO of Oxcia.